We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00882921
Recruitment Status : Completed
First Posted : April 17, 2009
Results First Posted : July 30, 2014
Last Update Posted : August 7, 2014
Information provided by (Responsible Party):

April 16, 2009
April 17, 2009
June 23, 2014
July 30, 2014
August 7, 2014
October 2008
February 2013   (Final data collection date for primary outcome measure)
Infusion-Related Adverse Event (IRAE) Rates Between IgG Anti-idursulfase Antibody Positive (Ab+) and Anti-idursulfase IgG Antibody Negative (Ab-) Patients [ Time Frame: Baseline to 109 Weeks ]
The primary analysis of how presence of antibodies affected IRAE rates was performed based on a negative binomial regression model. This was done to account for potentially differential follow-up time between antibody groups.
To evaluate the relative risk of experiencing an infusion-related adverse event given anti-idursulfase antibody positive status relative to anti-idursulfase antibody negative status. [ Time Frame: 2 years ]
Complete list of historical versions of study NCT00882921 on ClinicalTrials.gov Archive Site
Change From Baseline in uGAG Levels to 109 Weeks [ Time Frame: Baseline to 109 Weeks ]
Urine GAG
To measure the mean (and percent) difference in urinary GAG level between the groups of IgG anti-idursulfase antibody positive and anti-idursulfase IgG antibody negative patients. [ Time Frame: 2 years ]
Not Provided
Not Provided
An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients
A Multi-Center Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients Enrolled in the Hunter Outcome Survey (HOS) Receiving Idursulfase Enzyme Replacement Therapy
The objective of this study is to evaluate the effect of anti-idursulfase antibodies on idursulfase safety (measured by infusion related adverse events) between patients who develop anti-idursulfase antibodies and patients who do not after long-term idursulfase enzyme replacement therapy (ERT).
This study is being conducted to satisfy post-marketing commitments to monitor anti-idursulfase antibody development in Hunter syndrome patients after long-term idursulfase enzyme replacement therapy. The study will be conducted as a sub-study within the Hunter Outcome Survey (HOS). Hunter syndrome patients in the HOS who have previously received idursulfase as well as treatment-naive patients who will begin idursulfase treatment within 30 days of study enrollment will be included.
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Blood and urine
Non-Probability Sample
Patients with Hunter syndrome
Hunter Syndrome
Biological: Idursulfase
Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
Other Name: Elaprase
Idursulfase 0.5 mg/kg Weekly
Intervention: Biological: Idursulfase
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2013
February 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients must meet all of the following criteria to be considered eligible for enrollment:

  • The patient is male and enrolled in the HOS (i.e., meets the entry criteria of a documented diagnosis of Hunter syndrome)
  • The patient is ≥ 5 years-old
  • The patient is on idursulfase treatment or scheduled to begin idursulfase treatment within 30 days of study enrollment
  • The patient, patient's parent(s), or patient's legally authorized guardian must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient, patient's parent(s), or patient's legally authorized guardian.

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for this study:

  • The patient has received biologic/ERT products other than idursulfase, or other investigational product(s) for any reason within 30 days prior to study entry.
  • The patient has a life expectancy of < 2 years
  • The patient is unable to comply with the protocol, e.g., has a clinically relevant medical condition making implementation of the protocol difficult; has an uncooperative attitude; is unable to return for safety evaluations; or is otherwise unlikely to complete the study, as determined by the Investigator.
Sexes Eligible for Study: Male
5 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Brazil,   United Kingdom,   United States
Not Provided
Not Provided
Not Provided
Principal Investigator: Paul R Harmatz, MD Children's Hospital & Research Center Oakland
Principal Investigator: James E Wraith, MD Central Manchester University Hospitals, St. Mary's Hospital
Principal Investigator: Suresh Vijay, MD Birmingham Children's Hospital
Principal Investigator: Roberto Giugliani, MD, PhD Hospital de Clinicas de Porto Alegre
Principal Investigator: Nancy J Mendelsohn, MD Children's Hospitals and Clinics of Minnesota
Principal Investigator: Ashok Vellodi, MD Great Ormond Street Hospital
Study Director: Arian Pano, MD, MPH Shire Human Genetic Therapies, Inc.
July 2014